Drug class profile · refreshed daily from federal data

Parenteral Iron Replacement

5 molecules in this class, — combined CY2024 Part D spend across — claims. Class-level guide below for benefits decision-makers: where the money lives, where the savings live.

Last updated
NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annualOrange Book: weeklyShortages: daily

Class summary at a glance.

Every drug in the Parenteral Iron Replacement class tracked across NADAC, Part D Formulary, Part D Spending, FDA Orange Book, and shortage data. Ranked below by CY24 Part D spend. Click any molecule for the full drug profile.

Molecules in class
5tracked in Part D
CY24 Part D spend
—combined across class
Total Rx claims
—— unique beneficiaries
Generic mfrs (active)
5across all molecules

Every drug in this class, ranked by Part D spend.

CY2024 dataCMS Part D Spending Dashboard
01
Ferumoxytol
Brand: FeraBright · — Part D claims (CY24) · First FDA approval:
1 generic mfrs
Low NADAC—
→
Avg plan cost—
Part D spend —  
Class share
0%
of class CY24 spend
View profile →
02
Iron Sucrose
Brand: Venofer · — Part D claims (CY24) · First FDA approval:
3 generic mfrs
Low NADAC$12.21
→
Avg plan cost$12.21
Part D spend — 1× spread, current vs floor
Class share
0%
of class CY24 spend
View profile →
03
Sodium Ferric Gluconate Complex
Brand: Ferrlecit · — Part D claims (CY24) · First FDA approval:
1 generic mfrs
Low NADAC—
→
Avg plan cost—
Part D spend —  
Class share
0%
of class CY24 spend
View profile →
05
Venofer (Iron Sucrose)
— Part D claims (CY24) · First FDA approval:
Brand-only (no generics)
Low NADAC—
→
Avg plan cost—
Part D spend —  
Class share
0%
of class CY24 spend
View profile →